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Background: Consolidation durvalumab improved overall survival (OS) in locally advanced non-small
cell lung cancer (LA-NSCLC) treated with chemoradiotherapy (CRT) in the PACIFIC trial; however,
pneumonitis was increased with durvalumab. We sought to examine real-world outcomes with the PACIFIC
paradigm, especially factors associated with pneumonitis, using a multi-institutional review.
Methods: Patients with LA-NSCLC treated with CRT followed by durvalumab from January 2017–
February 2019 were identified at 2 institutions. We characterized demographics, tumor factors, radiotherapy,
and duration of durvalumab. We examined pneumonitis outcomes including re-challenge success, with
secondary endpoints of progression-free survival (PFS) and OS.
Results: Thirty-four patients were included with median follow-up of 12 months (range, 3 to 20 months);
94% had stage III disease. The cumulative grade >2 pneumonitis rate was 26.5% with 2 patients developing
grade 3 pneumonitis and no grade 4/5 events. Median time to pneumonitis after RT was 2.4 months
(range, 0 to 4.9 months). Pneumonitis management included median prednisone dose of 60 mg for median
taper of 6 weeks with durvalumab held for median of 4.5 weeks (range, 2 to 8 weeks); 70% of pneumonitis
patients received durvalumab re-challenge, with pneumonitis recurring in 14% of patients. 3-month and
6-month pneumonitis-free-survival were 76.9% and 73.6%, respectively; 9- and 12-month OS were 96%
(75.1–99.8%), 86.6% (63.5–95.5%), respectively; 9- and 12-month PFS were 68% (47.5–82.5%), 48.7%
(25.3–68.3%). Pneumonitis development did not significantly impact PFS or OS (P>0.05).
Conclusions: Among LA-NSCLC patients treated with CRT followed by consolidation durvalumab,
more than 25% developed symptomatic pneumonitis. In this small case series, pneumonitis did not appear to
negatively impact survival, and durvalumab re-challenge appeared feasible after pneumonitis treatment with
steroids.
Keywords: Non-small cell lung cancer (NSCLC); durvalumab; chemoradiotherapy (CRT); pneumonitis;
immune-related adverse events (irAE)
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Introduction
Non-small cell lung cancer (NSCLC) remains the leading
cause of cancer-related mortality in the US with more
than 30% of patients diagnosed with locally advanced
disease (1-3). The current standard of care for patients
with inoperable stage III NSCLC and a good performance
status is concurrent chemoradiotherapy (CRT) using
platinum-based doublet chemotherapy with the recent
addition of consolidation immunotherapy with the immune
checkpoint inhibitor (ICI) durvalumab (4-7). The addition
of consolidation immunotherapy is due to the recent
results of PACIFIC, a phase 3 randomized trial comparing
consolidation durvalumab versus placebo in patients with
unresectable stage III NSCLC who had not progressed after
definitive concurrent chemoradiation and demonstrated
significantly improved progression-free (PFS) and overall
survival (OS) (4).
While ICIs have prolonged survival for patients with
locally advanced NSCLC (LA-NSCLC), oncologists must
be aware of the potential for severe or life-threatening
immune-mediated adverse events, especially pneumonitis (8).
PACIFIC reported rates of pneumonitis of any grade for
durvalumab and placebo of 33.9% and 24.8%, respectively,
and grade 3 and 4 pneumonitis rates of 3.4% and 2.6%,
respectively. Pneumonitis was the most frequent adverse
event leading to the discontinuation of durvalumab and
led to discontinued treatment in 6.3% of patients (4).
In addition, pneumonitis can limit quality of life, lead
to oxygen dependence, and limit future therapeutic
interventions (9,10).
Radiation pneumonitis is among the most clinically
challenging toxicities following lung radiation and may
be exacerbated by consolidation immunotherapy. This
potential intensification of toxicity was highlighted in the
KEYNOTE-001 trial which used the checkpoint inhibitor
pembrolizumab for advanced NSCLC and observed
pulmonary toxicity of any grade in 63% of patients with
prior thoracic radiation versus 40% of patients without
thoracic radiation (11).
Our goals were to perform an analysis of real-world rates
of radiation pneumonitis in patients receiving definitive
chemoradiation and consolidation durvalumab for the
treatment of LA-NSCLC. Furthermore, we sought to
describe the impact of pneumonitis on durvalumab dose
intensity, and the safety of durvalumab re-challenge after
pneumonitis in the setting of definitive chemoradiation.
We present the following article in accordance with the
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STROBE reporting checklist (available at http://dx.doi.
org/10.21037/jtd-20-1792).
Methods
Study population
The study was conducted in accordance with the
Declaration of Helsinki (as revised in 2013).
After institutional review board of Washington
University in St. Louis HRPO# 201902048 and legal
approval, a multi-institution collaboration was established.
Individual consent for this retrospective analysis was waived.
Data was hosted and analyzed using a central repository
maintained with REDCap Software V7.3.5 (Vanderbilt
University, Nashville, Tennessee) (12).
Between January 2017 to February 2019, 84 patients with
LA-NSCLC treated with concurrent chemoradiation were
identified from both institutions. Patients were queried
from January 2017 as this was near the time of the adoption
of consolidation durvalumab in clinical practice. Patients
with stage IIB-IIIC NSCLC were included. Patients were
excluded if they received consolidative chemotherapy in
lieu of durvalumab, progressed during RT or soon after RT,
did not complete the full CRT course, had a pre-existing
autoimmune disorder that did not allow for durvalumab
administration, underwent prior thoracic RT, or underwent
neoadjuvant immunotherapy. The remaining cohort of
patients received consolidative durvalumab after definitive
CRT for LA-NSCLC. Ultimately, 50 patients were
excluded from the analysis (Figure 1).
Radiotherapy
RT was delivered using intensity modulated RT (IMRT)
technique for a planned course of 6–7 weeks of RT. All
patients were staged with computerized tomography (CT)
of the chest, positron emission tomography (PET), and/or
mediastinal staging with endobronchial ultrasound (EBUS)
or mediastinoscopy for equivocal PET findings. Patients
were followed with serial CT imaging at 6 weeks postRT, then typically every 3 months for 2 years, and every
6 months for an additional 3 years.
RT was delivered using IMRT technique for a planned
course of six to seven weeks of RT. Radiation simulation and
planning were performed using free-breathing and fourdimensional CT to assess tumor respiratory motion. Gross
tumor volumes (GTV) were contoured according to PET/

J Thorac Dis 2020;12(11):6690-6700 | http://dx.doi.org/10.21037/jtd-20-1792

6692

Hassanzadeh et al. Multi-institution pneumonitis review

Stage llB-IlIC NSCLC
undergoing definitive CRT
from 2017-2019
(n=84)

Excluded (n=50)
Received adjuvant chemotherapy			
(n=34)
Progression during RT or prior to adjuvant therapy		
(n=5)
Did not complete CRT				
(n=5)
Pre-existing autoimmune disorder			
(n=3)
Prior thoracic RT					(n=2)
Prior immunotherapy					(n=1)
(n=34)
Eligible patients who
received consolidation
durvalumab

Figure 1 CONSORT diagram of study population. NSCLC, non-small cell lung cancer; CRT, concurrent chemoradiation; RT,
radiotherapy.

CT avid primary tumor and nodal involvement. Internal
target volumes (ITV) were contoured accounting for
respiratory motion of GTV with a 5 to 7 mm expansion to
clinical target volume (CTV) followed by 5 mm expansion
to planning target volume (PTV). Dose constraints to
organs-at-risk (OARs) included spinal cord maximum
dose of less than 45 Gy, total lung mean dose less than
20 Gy, and heart V30 less than 50% and heart V50 less than
25%, brachial plexus maximum dose less than 66 Gy, and
esophagus mean dose less than 34 Gy. Lung dose-volume
histogram parameters were calculated as total lung volumes
subtracted from CTV (total lung-CTV) volumes, and are
referred to as lung V5, lung V20 with the utilization of dose
constraints including lung V20 less than 37% and V5 less
than 60%.

the Common Terminology Criteria for Adverse Events
(CTCAE) scoring system, version 5.0, using the following:
patient follow-up notes; CT, PET/CT, or magnetic
resonance imaging (MRI); endoscopy; echocardiography;
and cardiac catheterization.
Specifically, pneumonitis was determined using
documented clinical data regarding patient status, available
CT chest imaging, and physician assessment of pneumonitis
development given the constellation of findings. Physician
reporting of immune-related adverse events (irAE) were
also documented according to chart review. These irAE’s
were attributed to durvalumab when all other probable
causes were excluded.
Statistical analysis

Clinical endpoints
Patient, tumor, and treatment factors were investigated
and compiled into a de-identified database. The following
data was collected: age at diagnosis, cancer diagnosis and
staging, smoking status, patient demographics, concurrent
chemotherapy, concurrent radiation modality, details of
concurrent radiation including dose and fractionation,
durvalumab course including number of treatments,
and radiation dose parameters to the OARs. Patient
comorbidities were assessed using the Charlson comorbidity
index, adapted by Deyo et al. (13). Physician-reported
acute and late toxicity was queried and classified using
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Follow-up time was calculated from the end of radiation
therapy (RT). The primary endpoint of the study was
pneumonitis development and pneumonitis free survival
(time from the end of RT until pneumonitis development,
death or censoring at the date of last clinical followup). Pneumonitis that occurred during RT was coded as
0 months or considered to have occurred at the 0-time
point. Secondary endpoints were OS, PFS, and distant
metastasis free survival (DMFS). OS was determined as
the time from end of RT until death or date of last followup. PFS was determined as the time from end of RT until
first progression, death or date of last follow up. DMFS
was determined as the time from end of RT until first
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Table 1 (continued)
All patients (N=34)

Follow-up, median [range], months

Characteristics

12 [3–20]

Cisplatin/etoposide

Age, year
Median [range]

‡

Other
68 [37–84]

Median (range)
21 (53.8)

Female

13 (33.3)

24 (61.5)

Black or African-American

8 (20.5)

Asian

1 (2.6)

Unknown

1 (2.6)

1 (2.6)

60 [60–70]/30 [30–35]

Radiation modality, No. (%)

Race, No. (%)
White

3 (7.7)

Radiation dose/fractionation, Gy/fractions

Sex, No. (%)
Male

All patients (N=34)

IMRT

30 (76.9%)

Protons

4 (10.3%)

†

, ‘other’ stage included 1 patient with stage IIB and 1 patient
with recurrent stage IIIB; ‡, ‘other’ concurrent chemotherapy
included 1 patient receiving carboplatin/etoposide, percentages
may not total 100 because of rounding. ECOG, Eastern
Cooperative Oncology Group; NOS, not otherwise specified.

Stage, No. (%)
IIIA

20 (51.3)

IIIB

11 (28.2)

0

10 (25.6)

1

19 (48.7)

2

5 (12.8)

distant metastasis, death, or date of last follow up. KaplanMeier method was used for these endpoints. Potential
factors associated with development of pneumonitis were
investigated with univariate Cox proportional hazards
modeling. Subsequently, all variables with a P value less
than 0.05 or less were entered into the multivariable
analysis. All statistical tests were two-sided. A P value less
than 0.05 was considered statistically significant. All analysis
was completed using SPSS software, version 22.

Adenocarcinoma

15 (38.5)

Results

Squamous

12 (30.8)

Patient outcomes

Non-small cell, NOS

7 (17.9)

IIIC

1 (2.6)
†

Other

2 (5.1)

ECOG Performance Status Score (%)

Histology, No. (%)

Smoking status, No. (%)
Current smoker

7 (17.9)

Former smoker

25 (64.1)

Never smoker

2 (5.1)

Charlson/Deyo comorbidity score (%)
0

7 (20.6%)

1

9 (26.5%)

2

6 (17.6%)

≥3

12 (35.3%)

Concurrent chemotherapy, No. (%)
Carboplatin/paclitaxel
Table 1 (continued)
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30 (76.9)

A total of 34 patients treated from 2017 to 2019 for
clinical stage IIB to IIIC NSCLC treated with definitive
chemoradiation followed by consolidation durvalumab
were identified using the aforementioned selection
criteria (Table 1). Median follow up was 12 months (range,
3–20 months). Median age was 68 (range, 37 to 84 years)
with 21 males (61.7%) with 10 patients (29.4%) with
ECOG 0 performance status, 19 patients (55.8%) with
ECOG 1, and the remaining 5 patients (14.7%) with
ECOG 2.
The clinical staging for the patient cohort was 59% with
stage IIIA, 32% with stage IIIB, 1 patient with stage IIIC,
1 patient with recurrent stage IIIA disease, and 1 patient
with stage IIB. The median radiation dose and fractionation
was 60 Gy (range, 60–70 Gy) in 30 fractions (range, 30–35
fractions) and was delivered over a median of 43 days (range,
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38–51 days).
The median lung V5 and V20 were 48.5% (range, 19.3–
65.0%) and 19.4% (range, 6.7–38.1%) and the median lung
mean dose was 11.6 Gy (range, 4.4–19.1 Gy). The median
esophagus mean dose was 22.9 Gy (range, 5.5–40.7 Gy) and
median esophagus V60 was 4.8% (range, 0–45.4%). Median
heart mean dose was 10.1 Gy (range, 0.4–43.0 Gy) and
median heart V50 was 41.8% (range, 12.8–53.2%).
Chemotherapy and immunotherapy
Definitive chemotherapy regimens included carboplatin/
paclitaxel (88.2%), cisplatin/etoposide (8.8%) and
carboplatin/etoposide (3%). One patient received
neoadjuvant chemotherapy with cisplatin/permetrexed.
A median number of 6 doses of chemotherapy were
a d m i n i s t e r e d d u r i n g RT. D u r v a l u m a b d o s e w a s
administered at a standard dose of 10 mg/kg intravenously
with no dose reductions for up to 12 months as tolerated.
Median number of durvalumab doses administered were 8.5
(range, 1–26 doses). The median time between completion
of radiation and start of durvalumab was 29 days (range,
18–128 days).
Impact and management of pneumonitis and irAE
Median time to pneumonitis from the end of RT
was 2.4 months (range, 0–4.9 months). There were 9
patients (26.5%) with grade >2 pneumonitis among
the entire cohort. Seven patients (20.6%) developed
grade 2 pneumonitis and 2 patients (5.9%) developed
grade 3 pneumonitis. No patients developed grade 4
or 5 pneumonitis. Pneumonitis-free survival for 3- and
6-month timepoints was 76.9% and 73.6%. Pneumonitis
development did not significantly impact PFS (70% with
pneumonitis vs. 49.2% without pneumonitis at 12 months,
P=0.91) or OS (100% vs. 82.4% at 12 months, P=0.31).
All patients who developed pneumonitis were prescribed
prednisone for symptom management at a median initial
dose of 60 mg (range, 40–60 mg) for a median taper
length of 6 weeks (range, 2–19 weeks). Initial prednisone
dosing was prescribed by medical oncologists in 89% of
patients with pneumonitis, and by the inpatient medical
team in 11% of patients. Durvalumab was held during
the initial steroid course for a median of 4.5 weeks (range,
2–8 weeks). After the initial steroid taper, 7 out of the 9
patients (77.87%) with pneumonitis were re-challenged
with durvalumab with 1 out of the 7 patients (14.3%)
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developing pneumonitis recurrence after durvalumab rechallenge.
Other physician-reported irAEs during patient’s
durvalumab course were noted in 7 patients (20.6%)
including autoimmune thyroiditis in 2 patients (5.9%),
immune-related diarrhea requiring prednisone taper in 1
patient (3%), vitiligo development requiring discontinuation
of durvalumab in 1 patient (3%), perforated duodenal ulcer
requiring surgical repair in 1 patient (3%) and immunerelated transaminitis requiring prednisone taper in 1 patient
(3%). Overall, 9 patients (26.5%) required discontinuation
of durvalumab due to any toxicity. Among these 9 patients,
6 patients discontinued for pneumonitis, 1 patient for
immune-related transaminitis, 1 patient for immune-related
diarrhea, and 1 patient for vitiligo development.
Survival outcomes
Median OS was not reached, while 9-, 12- and 18-month
OS rates were 96% (75.1–99.8%), 86.6% (63.5–95.5%)
and 74.6% (48.5–88.8%), respectively. Median PFS was
11.8 months (95% CI, 7.2–16.4 months), while 9-, 12-,
and 18-month PFS were 68% (47.5–82.5%), 48.7% (25.3–
68.3%), and 38.9% (15.5–61.3%), respectively. Median
DMFS was 11.9 months (95% CI, 11.1–16.7 months), while
9- and 12-month DMFS were 72% (51–85%) and 46.7%
(23.7–66.7%), respectively.
On univariate analysis for OS, there was no association
between age, race, smoking status, stage, histology, number
of durvalumab cycles administered, and comorbidity score
(P>0.05). On univariate analysis for PFS, patient age (P=0.01),
number of durvalumab cycles administered (P=0.002) and the
Charlson/Deyo comorbidity score (P=0.006) were associated
with worse PFS. Durvalumab cycles administered (P=0.003)
and comorbidity score (P=0.008) were also significantly
associated with PFS on multivariate analysis. On univariate
analysis for pneumonitis free survival, only lung V5 (P=0.03)
was significantly associated with pneumonitis free survival
(Figures 2,3, Table 2).
Discussion
Using a multi-institutional review of patients with LANSCLC, we investigated the real-world management of
patients receiving consolidative durvalumab in a curative
setting and reported the success of durvalumab re-challenge
after pneumonitis development. The PACIFIC trial
provides little clarity in real-time management of treatment-
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NR

12 month OS
87% (64–96%)
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Median pneumoFS
(95% CI)
NR

18 month OS
75% (49–89%)

No. at risk

6 month pneumoFS
73.6% (56.5–85.5%)

Pneumonitis free survival
100

0

3

6

34

Median PFS (95% CI)
11.8 mo (7.2–16.4 mo)

9
12
Time (months)

28

15

18

15

9 month PFS
68% (48–82%)

12 month PFS
49% (25–68%)

Pneumonitis free survival
(proportion)

Overall survival
(proportion)

Overall survival
100
90
80
70
60
50
40
30
20
10
0

3 month pneumoFS
76.9% (61.5–87.0%)

80
60
40
20
0

2

No. at risk

18 month PFS
39% (16–61%)

0

3

6
Time (months)

9

12

34

25

20

16

12

Figure 3 Pneumonitis-free survival. Shown as Kaplan-Meier
Progression free survival
(proportion)

Progression free survival
100
90
80
70
60
50
40
30
20
10
0

No. at risk

pneumonitis-free survival; CI, confidence interval; NR, not
reached.

0

3

34

6

9
Time

21

Median DMFS (95% CI)
11.9 mo (11.1–16.7 mo)

Distant metastatis free survival
(proportion)

curves. Tick marks indicate censored observations. PneumoFS,

12

15

18

7

9 month DMFS
72% (51–85%)

1

12 month DMFS
46.7% (23.7–66.7%)

Distant metastasis free survival
100
90
80
70
60
50
40
30
20
10
0

No. at risk

0

3

34

30

6
9
Time (months)
22

12

15

6

4

14

Figure 2 Overall survival, progression-free survival, and distant
metastasis-free survival. Shown as Kaplan-Meier curves. Tick
marks indicate censored observations. OS, overall survival; PFS,
progression-free survival; DMFS, distant metastasis-free survival;
CI, confidence interval; NR, not reached.
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related pneumonitis and our findings provide insight into
overseeing these challenging clinical dilemmas outside
of a clinical trial setting (4). Our results demonstrated
more than one-quarter of patients developed radiation
pneumonitis after definitive CRT and consolidation
durvalumab. Pneumonitis development did not appear to be
associated with survival outcomes and only 2 patients (5.9%)
developed grade 3 pneumonitis, with no patients developing
severe grade 4/5 pneumonitis. In those patients who
developed pneumonitis, re-challenge with durvalumab was
well tolerated after resolution of symptoms in appropriately
selected patients.
Our cumulative rate of grades 2–4 pneumonitis was
26.5% which is slightly higher than the previously published
incidence of pneumonitis with durvalumab consolidation.
However, this comparison to the randomized data is limited
due to the smaller cohort in our study population. In the
PACIFIC study, rates of grades 2–4 pneumonitis were 19%
in the durvalumab arm versus 12% in the placebo arm (4).
PACIFIC reported both pneumonitis and radiation
pneumonitis together since these entities are hard to
differentiate, with a combined pneumonitis (grades 1–5)
rate of 33.9% in the durvalumab arm compared to 24.8%
in the placebo arm. This is in contrast to the most recent
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Table 2 Univariate and multivariate analyses of factors associated with overall survival, progression-free survival, and pneumonitis-free survival
Variables

UVA

MVA

HR (95% CI)

P value

0.963 (0.89–1.04)

0.34

HR (95% CI)

P value

Overall survival and factors associated
Age, years
Race
White
Black or African-American
Other

Ref
2.44 (0.27–22.2)

0.43

0

0.99

Smoking status
Current smoker

Ref

Former smoker

0.61 (0.07–5.61)

0.663

Never smoker

0

0.989

Stage
IIIA

Ref

IIIB

0.92 (0.15–5.63)

0.93

0

0.99

Other
Histology
Adenocarcinoma

Ref

Squamous

2.04 (0.13–32.9)

0.62

Non-small cell, NOS

4.45 (0.46–42.9)

0.2

Total lung-PTV V5

0.98 (0.92–1.04)

0.52

Total lung-PTV V20

0.95 (0.85–1.06)

0.36

Total lung mean

0.89 (0.72–1.1)

0.29

Heart V50

0.96 (0.82–1.13)

0.65

Number of durvalumab cycles delivered

0.88 (0.77–1.01)

0.64

Charlson/Deyo Comorbidity Score

0.88 (0.58–1.33)

0.54

0.932 (0.88–0.98)

0.011**

Progression-free survival and factors associated
Age, years

NS

Race
White

Ref

Black or African-American

0.49 (0.06–4.00)

0.51

Other

0.98 (0.12–7.78)

0.98

Smoking status
Current smoker

Ref

Former smoker

0.34 (0.07–1.70)

0.19

Never smoker

0.54 (0.07–4.08)

0.55

Table 2 (continued)
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Table 2 (continued)
Variables

UVA
HR (95% CI)

MVA
P value

HR (95% CI)

P value

Stage
IIIA

Ref

IIIB

0.51 (0.14–1.90)

0.32

0

0.98

Other
Histology
Adenocarcinoma

Ref

Squamous

1.44 (0.29–7.3)

0.66

Non-small cell, NOS

3.83 (0.91–16.1)

0.07

Number of durvalumab cycles delivered

0.89 (0.82–0.96)

0.002**

0.89 (0.82–0.96)

0.003**

Charlson/Deyo comorbidity score

0.58 (0.39–0.86)

0.006**

0.55 (0.36–0.86)

0.01**

1.05 (0.98–1.13)

0.16

Pneumonitis-free survival and factors associated
Age, years
Smoking status
Current smoker

Ref

Former smoker

0.61 (0.08–4.94)

0.65

Never smoker

0.39 (0.02–4.66)

0.38

Stage
IIIA

Ref

IIIB

0.46 (0.09–2.17)

0.33

0

0.98

Other
Histology
Adenocarcinoma
Squamous

Ref
0.92 (0.26–3.25)

0.89

0

0.98

Total lung-PTV V5

0.95 (0.90–0.99)

0.03**

Total lung-PTV V20

0.96 (0.88–1.05)

0.39

Total lung mean

0.90 (0.76–1.06)

0.21

Number of durvalumab cycles delivered

0.92 (0.82–1.03)

0.14

Charlson/Deyo comorbidity score

1.08 (0.86–1.37)

0.51

Non-small cell, NOS

No factors were associated with overall survival. The number of durvalumab cycles delivered and comorbidity score were significantly
associated with progression free survival on multivariate analysis. Lung V5 was significantly associated with pneumonitis on univariate. **
denotes statistical significance. UVA, univariate; MVA, multivariate; OS, overall survival; PFS, progression free survival; NOS, not otherwise
specified; NS, not significant; HR, hazard ratio; CI, confidence interval.

© Journal of Thoracic Disease. All rights reserved.

J Thorac Dis 2020;12(11):6690-6700 | http://dx.doi.org/10.21037/jtd-20-1792

6698

Hassanzadeh et al. Multi-institution pneumonitis review

pre-durvalumab era randomized clinical trial, RTOG
0617 where the rate of acute grades 2–4 pneumonitis
was 9–10% and the rate of late grades 2–4 pneumonitis
was 9% in the standard dose arm (14). In addition to the
synergy between immunotherapy and radiation leading to
pneumonitis, chemotherapy may further potentiate this
effect. In our data set, 88% of patients received carboplatin/
paclitaxel chemoradiation. Carboplatin with taxane-based
chemotherapy has been identified as a risk factor for
pneumonitis development in patients receiving definitive
CRT for LA-NSCLC (9,15). However, there was no
association identified between chemotherapy choice and
pneumonitis development in our cohort.
Current guidelines regarding the safety of re-challenging
with ICIs after pneumonitis are sparse and usually favor
holding or discontinuing immunotherapy in lieu of rechallenging after resolution of symptoms (16-18). However,
this approach may unnecessarily restrict patient access to
therapy that may provide life-prolonging benefit. In our
cohort, re-challenge with durvalumab in patients who
previously discontinued durvalumab due to pneumonitis
was well tolerated with only 1 out of 7 patients developing
pneumonitis recurrence. While this is a small number
to draw strong conclusions from, our results appear to
contrast previously reported rates of pneumonitis and irAE
recurrence after re-challenge where 26% of patients had
recurrence of the initial irAE and 26% developed a new
irAE after re-challenge (19). Overall, the rate of high dose
glucocorticoid usage for our patient set was 26.5%, while
PACIFIC reported high dose glucocorticoid use of 8.8% (4).
The median time durvalumab was held was 4.5 weeks with a
median initial prednisone dose of 60 mg for a median taper
length of 6 weeks. This suggests that durvalumab may not
need to be held indefinitely in the event of pneumonitis.
Clinical practice guidelines for management of irAEs
from ICIs suggest re-challenging patients after proper
management of their irAE while cautioning of the risk of
irAE recurrence (20).
Our observed survival outcomes are comparable with
that of PACIFIC. Our 12-month OS rate was 86.6%
while PACIFIC demonstrated a 12-month OS of 83.1%.
Our median PFS was 11.8 months while PACIFIC had
a median PFS from randomization of 17.2 months.
However, our median DMFS rate of 11.9 months was
shorter than the reported median time to death or
distant metastasis of 28.3 months in PACIFIC (21). This
difference in DMFS could be explained by differences in
patient clinical factors between our two cohorts and our
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smaller study cohort.
In this current data set we reviewed the impact of
multiple variables on PFS, OS and pneumonitis free
survival. Interestingly, the development of pneumonitis did
not appear to be negatively associated with worse PFS or
OS outcomes. This is in contrast to a study by Suresh et
al which found an increased risk of death in patients with
NSCLC who developed checkpoint inhibitor associated
pneumonitis (22). The number of durvalumab cycles
administered and the pre-existing comorbidity score of
patients were associated with PFS on multivariate analyses.
While the number of durvalumab cycles and development
of pneumonitis did not appear to be associated with OS in
this series, given the association with PFS of durvalumab
and the potential for false negative findings in this small
series with limited power to detect survival impacts, these
results warrant confirmation in larger examinations.
Pneumonitis free survival was associated with lung V5
while lung V20 and lung mean dose were not significantly
associated with pneumonitis. In addition, although V20 and
mean lung dose are frequently used in clinical practice as
dose-volume parameters to reduce the risk of pneumonitis,
other dosimetric variables including V5 have also been
shown to be predictive as was shown in our study (10).
Low dose radiation exposure as represented by V5 may be
more important in pneumonitis risk when consolidation
immune checkpoint inhibitors (ICIs) are administered (23).
Additional investigation into dosimetric parameters and
their association with pneumonitis using a larger patient
dataset is necessary, especially when considering the
synergistic effects of radiation and ICIs contributing to
pneumonitis.
The limitations of this study include its retrospective
nature, and its small sample size. The conclusions drawn
from association of factors and outcomes with pneumonitis
may be limited due to this sample size. In addition, adequate
data was not available for some variables of interest
including number of pack-year smoking history, baseline
pulmonary function, and dosimetric data beyond previously
reported dose-volume lung parameters for pneumonitis.
However, the median follow-up time of our data set was
11 months, whereas the median time to pneumonitis was
nearly 2 months, with all pneumonitis events occurring
by 6 months. A larger body of retrospective data pooled
from multiple institutions in the future will be essential to
further understand the impact of durvalumab and other
immunotherapy on the development of pneumonitis after
CRT.
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